Épisodes

  • Health Policy and Medicaid Funding
    May 2 2025

    Advocacy and policy leaders Dr. Michael Repka and Rebecca Hyder join host Dr. Andrew Pouw to share their experiences and perspectives about the Academy's work engaging with policy stakeholders. The conversation reviews recent government healthcare funding debates that may affect Medicaid and the Children's Health Insurance Program (CHIP).

    For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

    Voir plus Voir moins
    39 min
  • Updates in the Treatment of Leber Hereditary Optic Neuropathy (LHON)
    Apr 17 2025

    In today’s episode, host Dr. Amanda Redfern invites Dr. Nancy Newman to share updates in the treatment of Leber hereditary optic neuropathy (LHON), covering several clinical trials underway that involve idebenone and gene therapy.

    For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

    Voir plus Voir moins
    36 min
  • Guidelines for the Diagnosis, Management, and Study of Autoimmune Retinopathy
    Apr 3 2025

    In today’s episode, host Dr. Jay Sridhar is joined by Dr. Bobeck Modjtahedi to discuss the American Academy of Ophthalmology's new guidelines on autoimmune retinopathy (AIR), recently published in Ophthalmology Retina. A member of the Academy’s task force on AIR and lead author, Dr. Modjtahedi discusses a new diagnostic framework for categorizing AIR as probable, possible, or unlikely based on specific clinical criteria. The guidelines address the challenges in diagnosing this rare condition that mimics inherited retinal diseases, and outline a standardized approach to classification for both clinical practice and research.

    For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

    Voir plus Voir moins
    27 min
  • Interventional Valve-Enhancing Trabeculotomy (iVEnT)
    Mar 20 2025

    Drs. Davinder Grover and Ronald Fellman join host Dr. Andrew Pouw to discuss their latest innovative surgical advancement: interventional valve-enhancing trabeculotomy (iVEnT), an angle-based minimally invasive glaucoma surgery (MIGS) procedure. Compared with a traditional goniotomy, this alternative approach may be less invasive, sparing tissue and offering faster visual recovery for glaucoma patients.

    For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

    Voir plus Voir moins
    51 min
  • Eye Care for Patients With Intellectual Disability
    Mar 6 2025

    Dr. Michael Puente joins host Dr. Ben Young to share his experience founding the first eye clinic specifically for adult and pediatric patients with intellectual developmental delay. Dr. Puente provides practical tips for all ophthalmologists to improve their care for this vulnerable population.

    For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

    Voir plus Voir moins
    53 min
  • Dilute Hypochlorous Acid for the Treatment of Periorbital Necrotizing Fasciitis
    Feb 20 2025

    Drs. Louise Mawn and Jonathan Siktberg sit down with host Dr. Amanda Redfern to share their work on a groundbreaking paradigm shift in the treatment of periorbital necrotizing fasciitis with dilute hypochlorous acid.

    For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

    Voir plus Voir moins
    25 min
  • 2025 Retina Update, Part 2: Photobiomodulation, OCT and OCTA Reimbursement, and Surgical Advances
    Feb 7 2025

    Drs. M. Ali Khan and Ajay Kuriyan join host Dr. Jay Sridhar to discuss updates in the retina space, including the FDA approval of photobiomodulation for dry age-related macular degeneration (AMD), OCT and OCTA reimbursement changes, and surgical technology advances.

    For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

    Voir plus Voir moins
    28 min
  • 2025 Retina Update, Part 1: Injectables in the Medical Retina Space
    Jan 23 2025

    Drs. Ashkan Abbey and Ehsan Rahimy join host Dr. Jay Sridhar to discuss recent developments in the medical retina and injectable space, including faricimab versus high-dose aflibercept, biosimilars for ranibizumab and aflibercept, off-label bevacaziumb shortages, dry age-related macular degeneration (AMD) therapies, private equity acquisitions, and the new drug pipeline.

    For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

    Voir plus Voir moins
    44 min